Bellicum Pharmaceuticals, Inc financial data

Industry
Pharmaceutical Preparations
Location
3730 Kirby Drive, Suite 1200, Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2023 - Nov 14, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -25 % -163%
Return On Equity 157 %
Return On Assets -158 % -290%
Operating Margin -1.58K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.72M shares +12.8%
Common Stock, Shares, Outstanding 9.72M shares +12.8%
Entity Public Float 9.21M USD -65.6%
Common Stock, Value, Issued 98K USD +12.6%
Weighted Average Number of Shares Outstanding, Basic 30.9M shares +0.24%
Weighted Average Number of Shares Outstanding, Diluted 30.9M shares +0.24%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.51M USD 0%
Research and Development Expense 18.6M USD -9.02%
General and Administrative Expense 6.71M USD +16.3%
Operating Income (Loss) -23.8M USD +3.7%
Nonoperating Income (Expense) 1.45M USD -82.9%
Net Income (Loss) Attributable to Parent -22.4M USD -37.8%
Earnings Per Share, Basic -0.72 USD/shares -279%
Earnings Per Share, Diluted -0.72 USD/shares -300%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.91M USD -79.5%
Assets, Current 6.85M USD -78.1%
Property, Plant and Equipment, Net 21K USD +16.7%
Assets 6.85M USD -78.1%
Accounts Payable, Current 526K USD -26.3%
Accrued Liabilities, Current 1.21M USD -61%
Liabilities, Current 3.77M USD -43.8%
Liabilities 2.25M USD -60.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -354K USD -0.28%
Retained Earnings (Accumulated Deficit) -592M USD -3.93%
Stockholders' Equity Attributable to Parent -27M USD -460%
Liabilities and Equity 6.85M USD -78.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.43M USD -0.83%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities -5K USD +28.6%
Common Stock, Shares Authorized 160M shares +100%
Common Stock, Shares, Issued 9.78M shares +12.7%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.44M USD -0.75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.91M USD -79.5%
Deferred Tax Assets, Valuation Allowance 135M USD +4.68%
Deferred Tax Assets, Gross 135M USD +4.68%
Operating Lease, Liability 0 USD
Payments to Acquire Property, Plant, and Equipment 5K USD -28.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -22.4M USD -37.7%
Property, Plant and Equipment, Gross 592K USD -63.1%
Depreciation, Depletion and Amortization 3K USD -40%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 1.45M USD -47.5%
Interest Expense -1K USD -101%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares